Technical Analysis for KALV - KalVista Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 12.31 1.57% 0.19
KALV closed up 1.57 percent on Friday, July 10, 2020, on 48 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line.
Earnings due: Jul 13
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Flat
Historical KALV trend table...

Date Alert Name Type % Chg
200 DMA Resistance Bearish 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
NR7 Range Contraction 1.57%
Wide Bands Range Expansion 1.57%
20 DMA Support Bullish 4.68%
Wide Bands Range Expansion 4.68%
Down 3 Days in a Row Weakness 4.68%
Fell Below 200 DMA Bearish 3.79%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

KalVista Pharmaceuticals, Inc., formerly Carbylan Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). The Company is developing a plasma kallikrein inhibitor, which is administered directly into the eye. The Company is engaged in advancing several product candidates developed from its portfolio into early clinical trials. The Company is progressing additional oral candidates towards regulatory preclinical studies. The Company's HAE product candidate, KVD818, is an inhibitor of plasma kallikrein. The Company has initiated clinical testing of KVD818 in a Phase I clinical trial. It has completed an open-label single ascending dose Phase I trial in DME patients with KVD001.
Medical Specialties Pharmaceutical Diseases Organ Systems Enzymes Diabetic Macular Edema Hereditary Angioedema Angioedema

Is KALV a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 18.9599
52 Week Low 5.605
Average Volume 146,548
200-Day Moving Average 12.38
50-Day Moving Average 11.22
20-Day Moving Average 11.59
10-Day Moving Average 12.30
Average True Range 0.92
ADX 26.25
+DI 26.71
-DI 14.77
Chandelier Exit (Long, 3 ATRs ) 10.88
Chandelier Exit (Short, 3 ATRs ) 12.38
Upper Bollinger Band 13.53
Lower Bollinger Band 9.64
Percent B (%b) 0.69
BandWidth 33.58
MACD Line 0.34
MACD Signal Line 0.33
MACD Histogram 0.0109
Fundamentals Value
Market Cap 119.56 Million
Num Shares 9.71 Million
EPS -3.07
Price-to-Earnings (P/E) Ratio -4.01
Price-to-Sales 202.03
Price-to-Book 4.72
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.08
Resistance 3 (R3) 13.09 12.84 12.95
Resistance 2 (R2) 12.84 12.65 12.84 12.90
Resistance 1 (R1) 12.58 12.53 12.71 12.57 12.86
Pivot Point 12.33 12.33 12.40 12.33 12.33
Support 1 (S1) 12.07 12.14 12.20 12.06 11.76
Support 2 (S2) 11.82 12.02 11.82 11.72
Support 3 (S3) 11.56 11.82 11.67
Support 4 (S4) 11.55